Voices
Kohei Shitara: Early Tumor Response Correlates with Longer Survival in KEYNOTE-585
Kohei Shitara/X

Kohei Shitara: Early Tumor Response Correlates with Longer Survival in KEYNOTE-585

Kohei Shitara, Director of the Department of Gastrointestinal Oncology at National Cancer Center Hospital East, shared a post on X:

“Pleased to share analysis of early endpoints in KEYNOTE 585, ESMO – Eur. Oncology, ESMO Open.

pCR, mPR, and downstaging showed associations with favorable EFS and OS in gastric/GEJ adenocarcinoma treated with perioperative pembro+chemo. Further validation is warranted.”

Kohei Shitara

Title: Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma

Authors: K. Shitara, Y.-J. Bang, L.S. Wyrwicz, S.Y. Rha, T. Oshima, F. Pietrantonio, Y.-K. Park, S. Lonardi, P. Yañez, C.-J. Yen, J.-P. Metges, M. Garrido, M. Moehler, S. Pelles-Avraham, W.P. Yong, A. Spallanzani, E. Jensen, R. Krishnan, C.-S. Shih, S.-E. Al-Batran

Read The Full Article

Kohei Shitara

Other articles about KEYNOTE-585 on OnocDaily.

A. Spallanzani C.-J. Yen C.-S. Shih cancer E. Jensen F. Pietrantonio J.-P. Metges K. Shitara KEYNOTE-585 Kohei shitara L.S. Wyrwicz M. Garrido M. Moehler OncoDaily Oncology P. Yañez R. Krishnan S. Lonardi S. Pelles-Avraham S.-E. Al-Batran S.Y. Rha T. Oshima W.P. Yong Y.-J. Bang Y.-K. Park